Loading
A phase 2 trial of [18F]F-AraG in non-small-cell lung cancer, run by CellSight Technologies, Inc., now recruiting.
Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG is a phase 2 interventional study registered as NCT06107374 by CellSight Technologies, Inc., with 20 participants planned, started 2023-11-01 and due to reach its primary completion in 2025-12-31. Interventions recorded: [18F]F-AraG.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CellSight Technologies, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1, PD-1, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1, PD-1, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1, PD-1, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/